On February 21, 2018, Biocon reported that the FDA issued a Form 483 with six observations after the FDA completed a pre-approval inspection of the facility where Biocon plans to manufacture, in collaboration with Mylan, its follow-on insulin version of Lantus. Biocon indicated that it intends to respond to the FDA in a timely matter.

On February 26, 2018, according to the Korea Herald, Polus BioPharm said that it will issue convertible bonds worth $18,600,000 to fund production of a follow-on/biosimilar version of Lantus. Polus plans to use the funds to complete its new manufacturing plant, where its product will be produced for clinical trials. It also plans to file investigational new drug applications with both the FDA and the EMA. A Polus official is quoted as saying that Polus “plan[s] to expand [its] market share by offering up to a 50 percent discount compared to the original drug.”

Featured Editor

Updated Guide to the Biosimilars Patent Dance

In-house attorneys and executives can request a gratis copy of Goodwin's updated Guide to the Biosimilars Patent Dance

Biosimilars Regulatory IP Guide

Biosimilars: A Guide to Regulatory and Intellectual Property Issues

Subscribe

Big Molecule Watch Monthly DigestMonthly Digest provides analyses on regulatory issues, litigation, legislation, and other news in the ever-developing world of biosimilars. Subscribe>>

Get Real Time Blog PostsYou will receive a verification email once you submit this form to activate your real time Feedburner email subscription to Goodwin Procter - Big Molecule Watch Blog. Subscribe>>